source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-03 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE OF THE TRUST'S COMMON SHARES (NYSE: XFLT). THE TRUST ALSO DECLARED PREFERRED DIVIDENDS FOR THE QUARTER OF $0.40625 PER SHARE OF THE TRUST'S 6.50% SERIES 2026 TERM PREFERRED SHARES (NYSE: XFLTPRA). THE FOLLOWING DATES APPLY TO EACH DECLARATION: SHARE CLASS EX-DIVIDEND DATE RECORD DATE PAYABLE DATE AMOUNT CHANGE FROM PREVIOUS DECLA
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION AND QUARTERLY PREFERRED SHARES DIVIDEND
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-08 19:37:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS ENTERED INTO A PURCHASE AGREEMENT WITH CERTAIN INSTITUTIONAL INVESTORS FOR THE PURCHASE AND SALE OF 400,000 SHARES OF ITS 6.50% SERIES 2026 TERM PREFERRED SHARES (THE “PREFERRED SH
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST ANNOUNCES DIRECT OFFERING OF PREFERRED SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-01 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON OCTOBER 1, 2021 TO COMMON SHAREHOLDERS OF RECORD AS OF SEPTEMBER 15, 2021, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT. THE FOLLOWING DATES APPLY TO THE DECLARATION: EX-DIVIDEND DATE SEPTEMBER 14, 2021
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.073 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-02 16:15:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES (NYSE: XFLT), PAYABLE ON SEPTEMBER 1, 2021 TO COMMON SHAREHOLDERS OF RECORD AS OF AUGUST 17, 2021, AS NOTED BELOW. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT. THE FOLLOWING DATES APPLY TO THE DECLARATION: EX-DIVIDEND DATE AUGUST 16, 2021 RECORD
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES ITS MONTHLY COMMON SHARES DISTRIBUTION OF $0.073 PER SHARE
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-23 16:30:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS CLOSED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 3,565,000 COMMON SHARES OF BENEFICIAL INTEREST (“COMMON SHARES”) AT AN OFFERING PRICE OF $8.50 PER COMMON SHARE. AS
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST CLOSES PUBLIC OFFERING OF COMMON SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-20 16:11:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF COMMON SHARES OF BENEFICIAL INTEREST (“COMMON SHARES”) PURSUANT TO THE FUND'S EFFECTIVE SHELF REGISTRATION STATEM
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST COMMENCES PUBLIC OFFERING OF COMMON SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-23 19:37:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS PRICED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF ITS NEWLY DESIGNATED 6.50% SERIES 2026 TERM PREFERRED SHARES (THE “PREFERRED SHARES”) PURSUANT TO THE TRUST'S EFFECT
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST PRICES PUBLIC OFFERING OF PREFERRED SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-25 08:32:00
| null |
CHICAGO--(BUSINESS WIRE)--XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST (THE “TRUST”) (NYSE: XFLT), A DIVERSIFIED, CLOSED-END MANAGEMENT INVESTMENT COMPANY WITH AN INVESTMENT OBJECTIVE TO SEEK ATTRACTIVE TOTAL RETURN WITH AN EMPHASIS ON INCOME GENERATION ACROSS MULTIPLE STAGES OF THE CREDIT CYCLE, HAS PRICED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF COMMON SHARES OF BENEFICIAL INTEREST (“COMMON SHARES”) PURSUANT TO THE FUND'S EFFECTIVE SHELF REGISTRATION STATEMENT
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST PRICES PUBLIC OFFERING OF COMMON SHARES
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-01 22:30:00
| null |
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARED TRUST'S REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES, PAYABLE ON DECEMBER 31, 2019 TO COMMON SHAREHOLDERS OF RECORD AS OF DECEMBER 16, 2019. EX-DIVIDEND DATE IS DECEMBER 13, 2019.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES REGULAR MONTHLY DISTRIBUTION, PAYABLE ON DECEMBER 31, 2019
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-31 22:30:00
| null |
ON NOVEMBER 1, 2019, XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARED TRUST'S REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE TRUST'S COMMON SHARES, PAYABLE ON DECEMBER 2, 2019 TO COMMON SHAREHOLDERS OF RECORD AS OF NOVEMBER 15, 2019.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES REGULAR MONTHLY DISTRIBUTION, PAYABLE ON DECEMBER 2, 2019
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-01 22:30:00
| null |
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST HAS DECLARED ITS REGULAR MONTHLY DISTRIBUTION OF $0.073 PER SHARE ON THE COMPANY'S COMMON SHARES, PAYABLE ON NOVEMBER 1, 2019 TO COMMON SHAREHOLDERS OF RECORD AS OF OCTOBER 15, 2019. THE AMOUNT OF THE DISTRIBUTION REPRESENTS NO CHANGE FROM THE PREVIOUS MONTH'S DISTRIBUTION AMOUNT. THE EX-DIVIDEND DATE IS OCTOBER 14, 2019.
|
XAI OCTAGON FLOATING RATE & ALTERNATIVE INCOME TERM TRUST DECLARES REGULAR MONTHLY DISTRIBUTION, PAYABLE ON NOVEMBER 1, 2019
|
XFLT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-30 16:05:00
| null |
BOSTON, JUNE 30, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH RARE DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, EFFECTIVE ON JUNE 29, 2023, THE COMPANY ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 647,500 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE APPROVED BY X4'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS.
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-13 08:00:00
| null |
BOSTON, JUNE 13, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH RARE DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT IT EXPECTS TO BE ADDED TO THE BROAD-MARKET RUSSELL 3000 INDEX AT THE CONCLUSION OF THE 2023 RUSSELL INDEXES ANNUAL RECONSTITUTION, EFFECTIVE AFTER THE U.S. MARKET OPENS ON JUNE 26, 2023, ACCORDING TO A PRELIMINARY LIST OF ADDITIONS POSTED ON JUNE 9, 2023.
|
X4 PHARMACEUTICALS EXPECTED TO JOIN RUSSELL 3000® INDEX
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-02 16:05:00
| null |
BOSTON, JUNE 02, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH RARE DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, EFFECTIVE ON MAY 31, 2023, THE COMPANY ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 110,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE APPROVED BY X4'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS.
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-16 16:01:00
| null |
~60% REDUCTION IN ANNUALIZED INFECTION RATE SEEN IN THE MAVORIXAFOR ARM VS. PLACEBO (P75% REDUCTION IN THE PERCENTAGE OF INDIVIDUALS EXPERIENCING SEVERE INFECTIONS (GRADE 3 OR HIGHER) IN THE MAVORIXAFOR GROUP VS.
|
X4 PHARMACEUTICALS ANNOUNCES POSITIVE PHASE 3 RESULTS SHOWING MAVORIXAFOR REDUCED THE RATE, SEVERITY, AND DURATION OF INFECTIONS VS. PLACEBO IN PARTICIPANTS DIAGNOSED WITH WHIM SYNDROME
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-16 08:30:00
| null |
BOSTON, MAY 16, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH RARE DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT IT HAS AGREED TO SELL AN AGGREGATE OF 42,784,203 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) TO CERTAIN INSTITUTIONAL ACCREDITED INVESTORS IN A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING. X4 ANTICIPATES THAT GROSS PROCEEDS FROM THE PIPE WILL BE APPROXIMATELY $65 MILLION, BEFORE DEDUCTING FEES TO THE PLACEMENT AGENTS AND OTHER ESTIMATED OFFERING EXPENSES PAYABLE BY THE COMPANY.
|
X4 PHARMACEUTICALS ANNOUNCES $65 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-04 06:05:00
| null |
COMPANY TO HOST WEBINAR EVENT ON MAY 16 TH PRESENTING NEW CLINICAL DATA FROM THE 4WHIM PHASE 3 TRIAL; ORAL PRESENTATION TO FOLLOW ON MAY 21 ST AT THE 2023 CLINICAL IMMUNOLOGY SOCIETY (CIS) ANNUAL MEETING
|
X4 PHARMACEUTICALS REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-12 08:00:00
| null |
X4 TO HOST VIRTUAL INVESTOR EVENT ON TUESDAY, MAY 16 CIS ORAL PRESENTATION TO TAKE PLACE ON SUNDAY, MAY 21 BOSTON, APRIL 12, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT ITS SUBMITTED LATE-BREAKER ABSTRACT ENTITLED "RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME" HAS BEEN ACCEPTED FOR ORAL PRESENTATION AT THE ANNUAL MEETING OF THE CLINICAL IMMUNOLOGY SOCIETY (CIS), WHICH IS TAKING PLACE MAY 18-21, 2023, IN ST. LOUIS, MO. NEW DATA RELATED TO CLINICAL SECONDARY ENDPOINTS, AMONG OTHER ASSESSMENTS, ARE TO BE PRESENTED.
|
X4 PHARMACEUTICALS ANNOUNCES LATE-BREAKING ABSTRACT OF WHIM PHASE 3 CLINICAL DATA ACCEPTED FOR ORAL PRESENTATION AT THE 2023 ANNUAL MEETING OF THE CLINICAL IMMUNOLOGY SOCIETY (CIS)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-04 16:05:00
| null |
BOSTON, APRIL 04, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, EFFECTIVE ON MARCH 31, 2023, THE COMPANY ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 595,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE APPROVED BY X4'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS.
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-21 06:05:00
| null |
UPCOMING EXPECTED MILESTONES FOR INVESTIGATIONAL THERAPY MAVORIXAFOR IN WHIM SYNDROME INCLUDE: PRESENTATION OF ADDITIONAL PHASE 3 CLINICAL DATA IN 2Q 2023, NDA SUBMISSION IN EARLY
|
X4 PHARMACEUTICALS REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-02 16:05:00
| null |
BOSTON, MARCH 02, 2023 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, EFFECTIVE ON FEBRUARY 28, 2023, THE COMPANY ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 54,900 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE APPROVED BY X4'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS.
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-12 08:30:00
| null |
ORAL PRESENTATION FURTHER DETAILS POSITIVE DATA FROM MAVORIXAFOR PHASE 1B CLINICAL TRIAL IN PEOPLE WITH CHRONIC IDIOPATHIC, CYCLIC, OR CONGENITAL NEUTROPENIA
|
X4 PHARMACEUTICALS' PRESENTATIONS AT ASH 2022 FURTHER HIGHLIGHT OPPORTUNITY FOR MAVORIXAFOR IN THE TREATMENT OF CHRONIC NEUTROPENIA
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-07 08:43:00
| null |
BOSTON, DEC. 07, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH DISEASES OF THE IMMUNE SYSTEM, ANNOUNCED TODAY THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 52,300,000 SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE 6,800,000 SHARES OF ITS COMMON STOCK, AND ACCOMPANYING CLASS C WARRANTS TO PURCHASE 29,550,000 SHARES OF ITS COMMON STOCK AT AN EXERCISE PRICE OF $1.50 PER SHARE OF COMMON STOCK (OR, FOR INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK) AT A PRICE TO THE PUBLIC OF $1.10 PER SHARE AND ACCOMPANYING CLASS C WARRANT (OR $1.099 PER PRE-FUNDED WARRANT AND ACCOMPANYING CLASS C WARRANT). X4 HAS ALSO GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 8,865,000 SHARES OF ITS COMMON STOCK AND/OR CLASS C WARRANTS TO PURCHASE UP TO AN ADDITIONAL 4,432,500 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. X4'S GROSS PROCEEDS FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $65.0 MILLION (OR APPROXIMATELY $74.8 MILLION IF THE UNDERWRITERS EXERCISE THEIR OPTION IN FULL), BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND ESTIMATED OFFERING EXPENSES AND ANY PROCEEDS FROM THE EXERCISE OF THE WARRANTS TO BE ISSUED IN THE OFFERING. ALL OF THE SECURITIES IN THE OFFERING ARE BEING SOLD BY X4. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT DECEMBER 9, 2022, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.
|
X4 PHARMACEUTICALS PRICES $65.0 MILLION PUBLIC OFFERING
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-06 18:26:00
| null |
BOSTON, DEC. 06, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH DISEASES OF THE IMMUNE SYSTEM, ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS TO PURCHASE ITS COMMON STOCK IN LIEU THEREOF) AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS). IN ADDITION, X4 EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL SHARES OF ITS COMMON STOCK AND/OR WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SECURITIES IN THE OFFERING WILL BE SOLD BY X4. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.
|
X4 PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-04 16:05:00
| null |
BOSTON, NOV. 04, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL-MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, EFFECTIVE ON NOVEMBER 3, 2022, THE COMPANY ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 410,000 SHARES OF X4'S COMMON STOCK, OF WHICH AN OPTION TO PURCHASE 341,000 SHARES OF X4'S COMMON STOCK WAS GRANTED TO MARK BALDRY IN CONNECTION WITH HIS EMPLOYMENT AS X4'S CHIEF COMMERCIAL OFFICER. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE APPROVED BY X4'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OR BY A MAJORITY OF THE BOARD OF DIRECTORS.
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-03 06:05:00
| null |
FOLLOWING POSITIVE MAVORIXAFOR PHASE 1B DATA RELEASE IN MULTIPLE CHRONIC NEUTROPENIC DISORDERS, X4 CONTINUES TO LOOK FORWARD TO TOP-LINE RESULTS FROM ITS PIVOTAL PHASE 3 TRIAL IN WHIM SYNDROME IN THE FOURTH QUARTER OF 2022
|
X4 PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-26 08:00:00
| null |
A SEASONED LEADER IN THE LAUNCH OF RARE AND SPECIALTY PHARMACEUTICALS, MR. BALDRY IS EXPECTED TO JOIN X4 ON NOVEMBER 3, 2022
|
X4 PHARMACEUTICALS ANNOUNCES APPOINTMENT OF INDUSTRY VETERAN MARK BALDRY AS CHIEF COMMERCIAL OFFICER
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-27 07:50:00
| null |
100% OF STUDY PARTICIPANTS (N=25) ACHIEVED ROBUST RESPONSES TO ORAL MAVORIXAFOR
|
X4 PHARMACEUTICALS ANNOUNCES NEW POSITIVE PHASE 1B DATA SUPPORTING MAVORIXAFOR'S BROAD POTENTIAL IN CHRONIC NEUTROPENIA (CN)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-31 08:30:00
| null |
WEBCAST TO TAKE PLACE ON SEPTEMBER 27 AT 8:00 A.M. ET, FOLLOWED BY LIVE Q&A WEBCAST TO TAKE PLACE ON SEPTEMBER 27 AT 8:00 A.M. ET, FOLLOWED BY LIVE Q&A
|
X4 PHARMACEUTICALS TO HOST INVESTOR WEBINAR HIGHLIGHTING NEW MAVORIXAFOR PHASE 1B DATA IN CHRONIC NEUTROPENIA
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-04 07:05:00
| null |
HIGHLIGHTS NOTABLE UPCOMING MILESTONES INCLUDING DATA FROM PHASE 1B TRIAL IN CHRONIC NEUTROPENIA, EXPECTED IN LATE SEPTEMBER, AND RESULTS FROM GLOBAL, PIVOTAL PHASE 3 TRIAL IN WHIM SYNDROME, EXPECTED IN 4Q 2022
|
X4 PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-01 16:30:00
| null |
BOSTON, JULY 01, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, ON JUNE 30, 2022 THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 21,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-30 19:52:00
| null |
BOSTON, JUNE 30, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH RARE IMMUNE SYSTEM DISORDERS, TODAY ANNOUNCED THAT IT HAS AGREED TO SELL AN AGGREGATE OF 50,925,365 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE AN AGGREGATE OF 50,925,365 SHARES OF COMMON STOCK, TO CERTAIN INSTITUTIONAL ACCREDITED INVESTORS IN A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING. X4 ANTICIPATES THAT GROSS PROCEEDS FROM THE PIPE WILL BE APPROXIMATELY $55 MILLION, BEFORE DEDUCTING FEES TO THE PLACEMENT AGENT AND OTHER ESTIMATED OFFERING EXPENSES PAYABLE BY THE COMPANY. THE CLOSING OF THE FINANCING IS EXPECTED TO OCCUR ON OR ABOUT JULY 6, 2022, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.
|
X4 PHARMACEUTICALS ANNOUNCES $55 MILLION PRIVATE PLACEMENT FINANCING AND DEBT FACILITY AMENDMENT EXTENDING INTEREST-ONLY PERIOD BY UP TO 12 MONTHS
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-12 06:05:00
| null |
TOP-LINE DATA FROM PIVOTAL 4WHIM PHASE 3 CLINICAL TRIAL IN WHIM SYNDROME EXPECTED IN 4Q22
|
X4 PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-02 16:05:00
| null |
BOSTON, MAY 02, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, ON APRIL 29, 2022, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 21,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-01 16:05:00
| null |
BOSTON, APRIL 01, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, ON MARCH 31, 2022 THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 92,850 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-17 06:05:00
| null |
TOP-LINE DATA FROM PIVOTAL 4WHIM PHASE 3 CLINICAL TRIAL IN WHIM SYNDROME EXPECTED IN 4Q22
|
X4 PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-02 16:05:00
| null |
BOSTON, FEB. 02, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, ON JANUARY 31, 2022, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 33,000 SHARES OF X4'S COMMON STOCK AND RESTRICTED STOCK UNITS COVERING 11,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-05 16:05:00
| null |
BOSTON, JAN. 05, 2022 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, ON DECEMBER 31, 2021, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 37,650 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-13 08:00:00
| null |
- PRESENTED DATA HIGHLIGHT MAVORIXAFOR'S ABILITY TO RAISE THE SPECTRUM OF WHITE BLOOD CELL COUNTS ACROSS A BROAD RANGE OF DISEASES WITH OR WITHOUT CXCR4 MUTATIONS INCLUDING CHRONIC NEUTROPENIA -
|
X4 PHARMACEUTICALS PRESENTS NEW CLINICAL AND SCIENTIFIC DATA AT 2021 ASH ANNUAL MEETING SUPPORTING BROADER POTENTIAL FOR MAVORIXAFOR IN THE TREATMENT OF PRIMARY IMMUNODEFICIENCIES
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-11 09:00:00
| null |
- CXCR4 ANTAGONISM PROOF OF CONCEPT ESTABLISHED, WITH 100% OVERALL RESPONSE RATE TO COMBINATION TREATMENT IN FRONTLINE AND REFRACTORY PATIENTS -
|
X4 PHARMACEUTICALS PRESENTS NEW CLINICAL DATA AT ASH 2021 FURTHER SUPPORTING POTENTIAL OF MAVORIXAFOR + IBRUTINIB TO TREAT PATIENTS WITH DOUBLE-MUTATION WALDENSTRÖM'S MACROGLOBULINEMIA
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-02 06:05:00
| null |
COMPANY TO PRESENT NEW CLINICAL DATA SUPPORTING THE EXPANDED POTENTIAL USE OF MAVORIXAFOR TO TREAT A BROAD ARRAY OF IMMUNODEFICIENCIES AS WELL AS NEW INSIGHTS INTO WHIM SYNDROME
|
X4 PHARMACEUTICALS TO HOST VIRTUAL SEMINAR “UNDERSTANDING PRIMARY IMMUNODEFICIENCIES” TO HIGHLIGHT BROADENING MARKET OPPORTUNITIES FOR MAVORIXAFOR
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-01 16:05:00
| null |
BOSTON, DEC. 01, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PATIENTS WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT, ON NOVEMBER 30, 2021, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 SHARES OF X4'S COMMON STOCK AND RESTRICTED STOCK UNITS COVERING 25,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-10 08:00:00
| null |
BOSTON, NOV. 10, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL CXCR4-TARGETED SMALL MOLECULE THERAPEUTICS TO BENEFIT PEOPLE WITH DISEASES OF THE IMMUNE SYSTEM, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT STIFEL'S VIRTUAL HEALTHCARE CONFERENCE ON WEDNESDAY, NOVEMBER 17, 2021.
|
X4 PHARMACEUTICALS TO PARTICIPATE IN STIFEL'S VIRTUAL HEALTHCARE CONFERENCE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-04 09:01:00
| null |
DATA CONTINUE TO SUPPORT MAVORIXAFOR'S POTENTIAL TO BENEFIT PATIENTS WITH WHIM SYNDROME, CHRONIC NEUTROPENIA, AND WALDENSTRÖM'S MACROGLOBULINEMIA
|
X4 PHARMACEUTICALS TO HAVE STRONG PRESENCE AT ASH 2021 WITH SEVEN ACCEPTED ABSTRACTS HIGHLIGHTING NEW CLINICAL AND SCIENTIFIC DATA; COMPANY REPORTS THIRD QUARTER FINANCIAL RESULTS
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-19 08:00:00
| null |
EACH BRINGS SIGNIFICANT EXPERIENCE IN STRATEGIC MARKETING OF RARE DISEASE THERAPEUTICS AND COMMERCIAL OPERATIONS EACH BRINGS SIGNIFICANT EXPERIENCE IN STRATEGIC MARKETING OF RARE DISEASE THERAPEUTICS AND COMMERCIAL OPERATIONS
|
X4 PHARMACEUTICALS EXPANDS COMMERCIAL LEADERSHIP EXPERTISE WITH APPOINTMENT OF FRANÇOISE DE CRAECKER TO BOARD OF DIRECTORS AND KAROLYN PARK AS VICE PRESIDENT, U.S. COMMERCIAL
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 16:05:00
| null |
BOSTON, OCT. 01, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT, ON SEPTEMBER 30, 2021, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED INDUCEMENT AWARDS TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 95,200 SHARES OF X4'S COMMON STOCK AND RESTRICTED STOCK UNITS COVERING 6,000 SHARES OF X4'S COMMON STOCK. THESE STOCK AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-22 16:05:00
| null |
BOSTON, JULY 22, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021, AND PROVIDE AN UPDATE ON RECENT BUSINESS HIGHLIGHTS, ON AUGUST 3, 2021.
|
X4 PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2021 FINANCIAL RESULTS AND HOST A CONFERENCE CALL AND WEBCAST ON AUGUST 3, 2021
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-01 16:01:00
| null |
BOSTON, JULY 01, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT, ON JUNE 30, 2021, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED AN INDUCEMENT AWARD TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 10,850 SHARES OF X4'S COMMON STOCK AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-11 03:00:00
| null |
ROBUST DECREASES IN SERUM IGM AT LOW- AND MID-DOSES SUGGEST BEST-IN-CLASS POTENTIAL FOR MAVORIXAFOR PLUS IBRUTINIB THERAPY IN DOUBLE-MUTATION WALDENSTRÖM'S PATIENTS; MEANINGFUL INCREASES IN HEMOGLOBIN LEVELS SUGGEST REDUCTION IN CANCER BURDEN IN BONE MARROW
|
X4 PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSITIVE DATA FROM ONGOING PHASE 1B CLINICAL TRIAL OF MAVORIXAFOR IN WALDENSTRÖM'S MACROGLOBULINEMIA AT EHA 2021
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-12 10:00:00
| null |
INITIAL DATA FROM FIRST COHORT OF PATIENTS INDICATE MAVORIXAFOR PLUS IBRUTINIB TO BE WELL TOLERATED, WITH ENCOURAGING DECREASES IN SERUM IGM OBSERVED
|
X4 PHARMACEUTICALS ANNOUNCES POSITIVE PRELIMINARY DATA FROM ONGOING PHASE 1B CLINICAL TRIAL OF MAVORIXAFOR IN WALDENSTRÖM'S MACROGLOBULINEMIA AS PUBLISHED IN EHA ABSTRACT
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-06 08:00:00
| null |
COMPANY CONTINUES TO MAKE SIGNIFICANT CLINICAL PROGRESS WITH LEAD CANDIDATE MAVORIXAFOR ACROSS MULTIPLE RARE DISEASE INDICATIONS
|
X4 PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-22 08:00:00
| null |
BOSTON, APRIL 22, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2021, AND PROVIDE AN UPDATE ON RECENT BUSINESS HIGHLIGHTS, ON MAY 6, 2021.
|
X4 PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2021 FINANCIAL RESULTS AND HOST A CONFERENCE CALL AND WEBCAST ON MAY 6, 2021
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-07 08:00:00
| null |
BOSTON, APRIL 07, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT A CORPORATE OVERVIEW AT THE 20TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON MONDAY, APRIL 12, 2021.
|
X4 PHARMACEUTICALS TO PRESENT AT THE 20TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-19 08:01:00
| null |
BOSTON, MARCH 19, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT IT HAS AGREED TO SELL AN AGGREGATE OF 6,321,837 SHARES OF ITS COMMON STOCK, INCLUDING PRE-FUNDED WARRANTS TO PURCHASE COMMON STOCK, TO CERTAIN INSTITUTIONAL ACCREDITED INVESTORS IN A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING. X4 ANTICIPATES THAT GROSS PROCEEDS FROM THE PIPE WILL BE APPROXIMATELY $55.0 MILLION, BEFORE DEDUCTING FEES TO THE PLACEMENT AGENTS AND OTHER ESTIMATED OFFERING EXPENSES PAYABLE BY THE COMPANY, BASED ON THE OFFERING PRICE OF $8.70 PER SHARE (OR $8.69 PER PRE-FUNDED WARRANT), THE LAST REPORTED SALE PRICE OF X4'S COMMON STOCK ON THE NASDAQ GLOBAL MARKET ON MARCH 18, 2021.
|
X4 PHARMACEUTICALS ANNOUNCES $55.0 MILLION AT-THE-MARKET PRIVATE PLACEMENT FINANCING
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-04 16:01:00
| null |
BOSTON, JAN. 04, 2021 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT, ON DECEMBER 31, 2020, THE COMPENSATION COMMITTEE OF X4'S BOARD OF DIRECTORS ISSUED AN INDUCEMENT AWARD TO NEW EMPLOYEES UNDER THE X4 PHARMACEUTICALS, INC. 2019 INDUCEMENT EQUITY INCENTIVE PLAN (THE “2019 INDUCEMENT PLAN”). THE 2019 INDUCEMENT PLAN IS USED EXCLUSIVELY FOR THE GRANT OF EQUITY AWARDS TO INDIVIDUALS WHO WERE NOT PREVIOUSLY AN EMPLOYEE OF X4. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 156,050 SHARES OF X4'S COMMON STOCK AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH X4 IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-14 08:00:00
| null |
BOSTON, DEC. 14, 2020 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THE APPOINTMENT OF DIEGO CADAVID, M.D., AS CHIEF MEDICAL OFFICER. DR. CADAVID WILL BE RESPONSIBLE FOR THE STRATEGY, DIRECTION AND EXECUTION OF THE COMPANY'S CLINICAL DEVELOPMENT PROGRAMS.
|
X4 PHARMACEUTICALS APPOINTS DIEGO CADAVID, M.D., AS CHIEF MEDICAL OFFICER
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-10 08:00:00
| null |
BOSTON, DEC. 10, 2020 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THAT IT HAS RECEIVED RARE PEDIATRIC DISEASE (RPD) DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS LEAD ASSET, MAVORIXAFOR, FOR THE TREATMENT OF WHIM (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS) SYNDROME, A RARE, INHERITED, PRIMARY IMMUNODEFICIENCY DISEASE CAUSED BY GENETIC MUTATIONS IN THE CXCR4 RECEPTOR GENE. MAVORIXAFOR IS CURRENTLY BEING INVESTIGATED IN A GLOBAL PIVOTAL PHASE 3 CLINICAL TRIAL, 4WHIM, FOR THE TREATMENT OF WHIM SYNDROME IN PATIENTS WHO ARE 12 YEARS OF AGE AND OLDER.
|
X4 PHARMACEUTICALS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR MAVORIXAFOR FOR THE TREATMENT OF WHIM SYNDROME
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-02 08:00:00
| null |
CAMBRIDGE, MASS., NOV. 02, 2020 (GLOBE NEWSWIRE) -- X4 PHARMACEUTICALS, INC. (NASDAQ: XFOR), A LEADER IN THE DISCOVERY AND DEVELOPMENT OF NOVEL THERAPIES TARGETING DISEASES RESULTING FROM DYSFUNCTION OF THE CXCR4 PATHWAY, TODAY ANNOUNCED THE APPOINTMENT OF ART TAVERAS, PH.D., AS CHIEF SCIENTIFIC OFFICER. DR. TAVERAS WILL LEAD ALL RESEARCH AND NON-CLINICAL DEVELOPMENT FUNCTIONS SUPPORTING THE COMPANY'S PIPELINE OF INVESTIGATIONAL THERAPIES.
|
X4 PHARMACEUTICALS APPOINTS ART TAVERAS, PH.D., AS CHIEF SCIENTIFIC OFFICER
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-09-02 10:30:00
| null |
X4 PHARMACEUTICALS ANNOUNCES PUBLICATION OF MAVORIXAFOR PHASE 2 CLINICAL DATA FOR TREATMENT OF WHIM SYNDROME.X4 PHARMACEUTICALS INC - CONTINUES TO ADVANCE MAVORIXAFOR IN PHASE 3 PIVOTAL TRIAL IN WHIM USING OPTIMAL DOSE AND KEY ENDPOINTS FROM PHASE 2 TRIAL.X4 PHARMACEUTICALS INC - TO DATE, MAVORIXAFOR HAS BEEN WELL TOLERATED.
|
X4 PHARMACEUTICALS- CONTINUES TO ADVANCE MAVORIXAFOR IN PHASE 3 PIVOTAL TRIAL IN WHIM USING OPTIMAL DOSE AND KEY ENDPOINTS FROM PHASE 2 TRIAL
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-30 11:30:00
| null |
X4 PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.X4 PHARMACEUTICALS INC - HAD $105.6 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH, AS OF JUNE 30, 2020.X4 PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.76.
|
X4 PHARMACEUTICALS REPORTS QTRLY LOSS PER SHARE $0.76
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-07 10:30:00
| null |
X4 PHARMACEUTICALS PROVIDES CORPORATE UPDATE, INCLUDING EXPECTED IMPACT OF COVID-19, AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.X4 HAD $117.0 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH, AS OF MARCH 31, 2020.CONTINUES TO EXPECT THAT ITS CASH AND CASH EQUIVALENTS WILL FUND COMPANY OPERATIONS INTO EARLY 2022.TO DATE, COMPANY BELIEVES THAT COVID-19 HAS HAD MINIMAL EFFECT ON ITS ONGOING BUSINESS OPERATIONS.EXPECTS A DELAY INTO 2022 TO REPORT TOP-LINE DATA FROM ITS PIVOTAL PHASE 3 CLINICAL TRIAL IN WHIM SYNDROME.A DELAY INTO 2021 TO REPORT INITIAL DATA FROM ITS PHASE 1B TRIAL IN SEVERE CONGENITAL NEUTROPENIA DUE TO COVID-19 PANDEMIC.QTRLY LOSS PER SHARE OF $0.56.Q1 EARNINGS PER SHARE VIEW $-0.80 -- REFINITIV IBES DATA.
|
X4 PHARMACEUTICALS REPORTS Q1 2020 FINANCIAL RESULTS
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-12 11:30:00
| null |
X4 PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.X4 HAD $128.1 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH, AS OF DEC 31, 2019.QTRLY LOSS PER SHARE OF $0.66.Q4 EARNINGS PER SHARE VIEW $-0.83 -- REFINITIV IBES DATA.
|
X4 PHARMACEUTICALS REPORTS Q4 LOSS PER SHARE OF $0.66
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-12 11:30:00
| null |
X4 PHARMACEUTICALS GRANTED NEW COMPOSITION OF MATTER PATENT FOR LATE-STAGE CLINICAL CANDIDATE MAVORIXAFOR.X4 PHARMACEUTICALS INC - PATENT EXPECTED TO PROVIDE EXCLUSIVITY THROUGH 2038.
|
X4 PHARMACEUTICALS GRANTED NEW COMPOSITION OF MATTER PATENT FOR LATE-STAGE CLINICAL CANDIDATE MAVORIXAFOR
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-10 19:30:00
| null |
X4 PHARMACEUTICALS INC - ESTIMATES CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2019 TO BE APPROXIMATELY $130 MILLION.X4 PHARMACEUTICALS INC - CASH EXPECTED TO FUND OPERATIONS INTO 2022.
|
X4 PHARMA - ESTIMATES CASH AND CASH EQUIVALENTS AS OF DEC. 31, 2019 TO BE ABOUT $130 MLN
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-25 19:30:00
| null |
X4 PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING.X4 PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF COMMON STOCK AND CLASS B WARRANTS TO PURCHASE ITS COMMON STOCK.
|
X4 PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-12 12:30:00
| null |
X4 PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM THE FDA FOR MAVORIXAFOR FOR THE TREATMENT OF WHIM SYNDROME.
|
X4 RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR MAVORIXAFOR FOR TREATMENT OF WHIM SYNDROME
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-07 10:30:00
| null |
X4 PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $1.22.Q3 EARNINGS PER SHARE ESTIMATE $-1.07 -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, CASH, CASH EQUIVALENTS AND RESTRICTED CASH WERE $77.0 MILLION.
|
X4 PHARMACEUTICALS Q3 LOSS PER SHARE $1.22
|
XFOR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-30 09:00:00
| null |
SAN DIEGO, MAY 30, 2023 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE WILLIAM BLAIR 43R D ANNUAL GROWTH STOCK CONFERENCE, WHICH TAKES PLACE JUNE 6-8, 2023, IN CHICAGO AT THE LOEWS CHICAGO HOTEL. JOHN ABALLI, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND KAMAL ADAWI, EXAGEN'S CHIEF FINANCIAL OFFICER, WILL PRESENT ON WEDNESDAY, JUNE 7TH, AT 2:00 PM CT. INTERESTED PARTIES MAY ACCESS THE WEBCAST OF THE PRESENTATION USING A LINK ON EXAGEN'S WEBSITE AT HTTPS://INVESTORS.EXAGEN.COM/EVENTS.
|
EXAGEN INC. TO PARTICIPATE IN THE WILLIAM BLAIR 43RD ANNUAL GROWTH STOCK CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-20 16:05:00
| null |
RECORD AVISE® CTD VOLUME IN 2022 RECORD AVISE® CTD VOLUME IN 2022
|
EXAGEN INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-27 09:00:00
| null |
SAN DIEGO, FEB. 27, 2023 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING MARCH INVESTOR CONFERENCES.
|
EXAGEN INC. TO PARTICIPATE IN UPCOMING MARCH CONFERENCES
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-30 16:05:00
| null |
SAN DIEGO, JAN. 30, 2023 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE BTIG MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE, WHICH TAKES PLACE FEBRUARY 14-16, 2023 IN SNOWBIRD, UT. MANAGEMENT WILL BE PARTICIPATING IN ONE-ON-ONE MEETINGS WITH INVESTORS DURING THE EVENT; MEETINGS CAN BE REQUESTED THROUGH BTIG.
|
EXAGEN INC. TO PARTICIPATE IN THE 2023 BTIG MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-17 09:00:00
| null |
SAN DIEGO, OCT. 17, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), ANNOUNCED TODAY THAT THE COMPANY HAS APPOINTED JOHN ABALLI AS CEO AND PRESIDENT. LONGTIME CEO AND PRESIDENT RON ROCCA, WHO TOOK THE COMPANY PUBLIC AND BUILT A ROBUST GROWTH BUSINESS, IS STEPPING DOWN AFTER 11 YEARS AT THE HELM.
|
EXAGEN ANNOUNCES APPOINTMENT OF JOHN ABALLI AS CEO
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 08:25:00
| null |
SAN DIEGO, OCT. 04, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED THE APPOINTMENT OF ANDREW L. CONCOFF M.D. FACR, CAQSM AS CHIEF INNOVATION OFFICER. IN THIS ROLE, DR. CONCOFF WILL LEAD THE COMPANY'S RHEUMATOID ARTHRITIS MEDICAL INITIATIVES, INCLUDING THE AVISE® RADR PLATFORM (RHEUMATOID ARTHRITIS DRUG RESPONSE). DR. CONCOFF WILL BE A KEY PRINCIPAL IN STRATEGY, BUSINESS DEVELOPMENT, PORTFOLIO MANAGEMENT, PIPELINE PRIORITIZATION, AND FORMATION OF NEW BUSINESS VENTURES, AS WELL AS THE ADVANCEMENT OF INNOVATIVE ACCESS PARTNERSHIPS WITH PAYORS AND GOVERNMENTS GLOBALLY.
|
EXAGEN ANNOUNCES APPOINTMENT OF ANDREW L. CONCOFF MD, FACR, CAQSM, AS CHIEF INNOVATION OFFICER
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-20 16:05:00
| null |
SAN DIEGO, SEPT. 20, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THE ACCEPTANCE OF NINE ABSTRACTS AT THE 2022 AMERICAN COLLEGE OF RHEUMATOLOGY'S (ACR) ANNUAL MEETING, ACR CONVERGENCE 2022, BEING HELD NOVEMBER 10-14, 2022, AT THE PENNSYLVANIA CONVENTION CENTER IN PHILADELPHIA, PENNSYLVANIA.
|
EXAGEN ANNOUNCES ACCEPTANCE OF MULTIPLE ABSTRACTS AT ACR 2022 ANNUAL MEETING
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-01 16:05:00
| null |
SAN DIEGO, SEPT. 01, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THAT ITS COLLABORATION WITH DR. IÑAKI SANZ AT EMORY UNIVERSITY HAS LED TO A PUBLICATION IN NATURE, FOUND HERE. EXAGEN'S CLINICAL TEST OFFERINGS, RUN ON SAMPLES FROM SEVERE COVID-19 PATIENTS, HELPED RESEARCHERS FROM EMORY CHARACTERIZE THE AUTOIMMUNE PROFILES INDUCED BY SARS-COV-2 INFECTION.
|
EXAGEN INC. COLLABORATION LEADS TO CHARACTERIZATION OF BROAD AUTOREACTIVITY IN SEVERE COVID-19 PATIENTS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-04 16:06:00
| null |
SAN DIEGO, AUG. 04, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THE LAUNCH OF A PROSPECTIVE CLINICAL STUDY DESIGNED TO VALIDATE A NOVEL AND MINIMALLY INVASIVE GENOMIC DIAGNOSTIC TEST FOR RHEUMATOID ARTHRITIS USING THE AVISE® RADR PLATFORM. THE GOAL OF THE TREATMENT STRATIFICATION USING GENE EXPRESSION PROFILING IN RHEUMATOID ARTHRITIS (TIGER) STUDY IS TO ASSESS WHETHER CERTAIN BIOMARKERS FROM SYNOVIAL BIOPSIES OF INFLAMED JOINT TISSUE ACCURATELY PREDICT RESPONSE TO ANTIRHEUMATIC MEDICATIONS. THE TIGER STUDY IS THE NEXT STEP IN EXAGEN'S PROCESS OF BRINGING AVISE® RADR TO MARKET.
|
EXAGEN INITIATES STUDY TO PREDICT RHEUMATOID ARTHRITIS DRUG RESPONSE (RADR) IN PATIENTS WITH RA
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-05 08:25:00
| null |
SAN DIEGO, JULY 05, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED NEW ROBUST, REAL-WORLD EVIDENCE CONFIRMING AVISE® TESTING ENABLES DECISIVE CLINICAL ACTION IN THE DIFFERENTIAL DIAGNOSIS FOR LUPUS. THE COMPLEMENT ACTIVATION PRODUCTS VS. STANDARD ANA TESTING: TREATMENT OUTCOMES, DIAGNOSIS, AND ECONOMIC IMPACT IN SYSTEMIC LUPUS ERYTHEMATOSUS (CAPSTONE) STUDY IS THE LARGEST COMPARATIVE UTILITY STUDY IN LUPUS DIAGNOSIS AND WAS PUBLISHED IN THE JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY. THE STUDY LEVERAGED MULTIPLE EXTERNAL DATABASES ENCOMPASSING ELECTRONIC HEALTH RECORDS AND LINKED INSURANCE CLAIMS DATA ON NEARLY 50,000 PATIENT TESTS WITH AVISE OR STANDARD OF CARE LABS FROM HUNDREDS OF RHEUMATOLOGISTS ACROSS THE U.S., COMPARING DIAGNOSIS, TREATMENT, AND COST OF CARE OUTCOMES FOR NEW PATIENTS TESTED WITH AVISE LUPUS AND THOSE TESTED WITH A TRADITIONAL ANA (TANA) APPROACH, INCLUDING SPECIFIC AUTOANTIBODIES. THE FINDINGS REVEALED THAT THE AVISE LUPUS TEST IS MORE CLINICALLY EFFECTIVE, BOTH FOR PATIENTS WHO TEST POSITIVE AND THOSE WHO TEST NEGATIVE, AS COMPARED TO THE CURRENT STANDARD OF CARE.
|
EXAGEN RELEASES LARGEST COMPARATIVE UTILITY STUDY IN LUPUS DIAGNOSTICS CONFIRMING AVISE® LUPUS DELIVERS UNPARALLELED UTILITY
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-26 16:05:00
| null |
SAN DIEGO, MAY 26, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE WILLIAM BLAIR 42ND ANNUAL GROWTH STOCK CONFERENCE, WHICH TAKES PLACE JUNE 6-9, 2022, IN CHICAGO AT THE LOEWS CHICAGO HOTEL. RON ROCCA, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND KAMAL ADAWI, EXAGEN'S CHIEF FINANCIAL OFFICER, WILL PRESENT ON THURSDAY, JUNE 9TH, AT 12:40 PM CT. INTERESTED PARTIES MAY ACCESS THE WEBCAST OF THE PRESENTATION USING A LINK ON EXAGEN'S WEBSITE AT HTTPS://INVESTORS.EXAGEN.COM/EVENTS.
|
EXAGEN INC. TO PARTICIPATE IN THE WILLIAM BLAIR 42ND ANNUAL GROWTH STOCK CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-11 16:06:00
| null |
SAN DIEGO, MAY 11, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THAT MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) NORIDIAN HAS PROVIDED PRICING FOR AVISE® LUPUS. NORIDIAN'S DECISION TO PRICE AVISE LUPUS FOLLOWS THE APPROVAL BY THE AMERICAN MEDICAL ASSOCIATION (AMA) CPT® EDITORIAL PANEL OF PROPRIETARY LABORATORY CODE (PLA) CODE 0312U FOR AVISE LUPUS. THE PLA CODE HAS AN EFFECTIVE DATE OF APRIL 1, 2022.
|
EXAGEN INC. ANNOUNCES NEW PLA CODE AND MEDICARE PRICING FOR PROPRIETARY AVISE® LUPUS TEST
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-11 16:05:00
| null |
RECORDS IN ORDERING HEALTHCARE PROVIDERS AND ADOPTERS, SET ALL-TIME RECORD FOR AVISE® CTD MONTHLY VOLUME IN MARCH RECORDS IN ORDERING HEALTHCARE PROVIDERS AND ADOPTERS, SET ALL-TIME RECORD FOR AVISE® CTD MONTHLY VOLUME IN MARCH
|
EXAGEN INC. REPORTS FIRST QUARTER 2022 RESULTS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-01 12:00:00
| null |
SAN DIEGO, MAY 01, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED, IN RECOGNITION OF LUPUS AWARENESS MONTH, THE LAUNCH OF A FIVE-WEEK AWARENESS CAMPAIGN TO HIGHLIGHT IMPORTANT AND IMPACTFUL WORK BEING DONE TO HELP THOSE SUFFERING FROM SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).
|
EXAGEN ANNOUNCES FIVE-WEEK CAMPAIGN FOR LUPUS AWARENESS MONTH
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-30 08:25:00
| null |
SAN DIEGO, MARCH 30, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THAT AVISE® TESTS HAVE ENTERED INTO AN IN-NETWORK AGREEMENT WITH EVOLUTIONS HEALTHCARE SYSTEMS OFFERING ACCESS TO ENHANCED CARE TO PARTICIPATING MEMBERS. THE AGREEMENT INCLUDES EXAGEN'S AVISE® LUPUS AND AVISE® CTD TESTS MAKING AVISE DIAGNOSTIC TESTING AVAILABLE AS AN IN-NETWORK BENEFIT.
|
EXAGEN INC. EXPANDS IN-NETWORK ACCESS WITH EVOLUTIONS HEALTHCARE SYSTEMS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-22 16:06:00
| null |
SAN DIEGO, MARCH 22, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THAT AVISE® TESTS WILL SOON SURPASS 90 MILLION LIVES AS AN IN-NETWORK BENEFIT FOR PATIENTS. EFFECTIVE JUNE 1, 2022, AVISE TEST OFFERINGS BECOME AN IN-NETWORK, COVERED BENEFIT WITH CENTENE CORPORATION, INCLUDING ITS SUBSIDIARY WELLCARE HEALTH PLANS, PROVIDING ENHANCED CARE TO OVER 22.7 MILLION MEMBERS.
|
EXAGEN INC. EXPANDS IN-NETWORK BENEFIT WITH ADDITIONAL 22.7 MILLION LIVES
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-22 16:05:00
| null |
SIX QUARTERLY RECORDS: AVISE® CTD VOLUME, TESTING REVENUE, TESTING GROSS MARGIN, TESTING GROSS MARGIN PERCENT, ADOPTERS, AND ORDERING HEALTHCARE PROVIDERS SIX QUARTERLY RECORDS: AVISE® CTD VOLUME, TESTING REVENUE, TESTING GROSS MARGIN, TESTING GROSS MARGIN PERCENT, ADOPTERS, AND ORDERING HEALTHCARE PROVIDERS
|
EXAGEN INC. REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-16 16:05:00
| null |
SAN DIEGO, MARCH 16, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THE FORMATION OF ITS NEW SCIENTIFIC ADVISORY BOARD (SAB) WITH APPOINTMENT OF SEVEN DOCTORS AND RHEUMATOLOGY EXPERTS. THE SAB INCLUDES STANLEY COHEN, MD; ANDREW CONCOFF, MD, FACR, CAQSM; KEVIN DEANE, MD, PHD; PAUL J. DEMARCO, MD; HARRIS PERLMAN, PHD; ERIC RUDERMAN, MD; AND MARINA SIROTA, PHD.
|
EXAGEN ANNOUNCES NEW RHEUMATOID ARTHRITIS SCIENTIFIC ADVISORY BOARD
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-02 16:05:00
| null |
SAN DIEGO, FEB. 02, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE BTIG MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE, WHICH TAKES PLACE FEBRUARY 15-17, 2022. RON ROCCA, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND KAMAL ADAWI, EXAGEN'S CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT ON WEDNESDAY, FEBRUARY 16 AT 2:00 PM ET, WHICH IS ACCESSIBLE TO CONFERENCE ATTENDEES. MANAGEMENT WILL ALSO BE PARTICIPATING IN ONE-ON-ONE MEETINGS WITH INVESTORS DURING THE EVENT; MEETINGS CAN BE REQUESTED THROUGH BTIG.
|
EXAGEN INC. TO PARTICIPATE IN THE 2022 BTIG MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-09 12:00:00
| null |
SAN DIEGO, JAN. 09, 2022 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, AND QUEEN MARY UNIVERSITY OF LONDON, ANNOUNCED TODAY THE EXECUTION OF A RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT. THE COLLABORATION WILL FOCUS ON DEVELOPMENT AND OPTIMIZATION OF PATENT-PENDING PRECISION MEDICINE APPROACHES, BASED ON RNA EXPRESSION SIGNATURES, TO PERSONALIZE THERAPEUTIC AGENT SELECTION FOR RHEUMATOID ARTHRITIS (RA) PATIENTS. BOTH PARTIES WILL CONTRIBUTE TO THE DEVELOPMENT OF THE PATENT-PENDING ASSAYS, LEADING TO THE COMMERCIALIZATION OF NOVEL MOLECULAR ASSAYS THAT SEGMENT PATIENTS ACCORDING TO GENE EXPRESSION IN THEIR SYNOVIAL TISSUE BIOPSIES.
|
EXAGEN INC. AND QUEEN MARY UNIVERSITY OF LONDON ANNOUNCE EXCLUSIVE LICENSE AND COLLABORATION TO DEVELOP NOVEL PATENTED MOLECULAR SIGNATURES FOR RHEUMATOID ARTHRITIS BIOLOGIC THERAPEUTIC SELECTION
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-27 08:25:00
| null |
SAN DIEGO, OCT. 27, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THAT AVISE® CTD AND AVISE LUPUS ARE A CONTRACTED COVERED SERVICE WITH INLAND EMPIRE HEALTH PLAN (IEHP), PROVIDING ENHANCED CARE TO OVER 1.4 MILLION MEMBERS. THE AGREEMENT ALSO MAKES AVISE DIAGNOSTIC TESTING AVAILABLE AS AN IN-NETWORK BENEFIT.
|
EXAGEN INC. EXPANDS COVERAGE WITH INLAND EMPIRE HEALTH PLAN, PARTNERING TO PROVIDE MORE ACCURATE DIAGNOSTIC TESTING WITH AVISE® CTD AND AVISE LUPUS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-13 16:15:00
| null |
SAN DIEGO, SEPT. 13, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE CANTOR FITZGERALD VIRTUAL GLOBAL HEALTHCARE CONFERENCE WHICH TAKES PLACE SEPTEMBER 27-30TH, 2021. RON ROCCA, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND KAMAL ADAWI, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT ON MONDAY, SEPTEMBER 27TH AT 2:40 PM EDT.
|
EXAGEN INC. TO PARTICIPATE IN THE 2021 CANTOR FITZGERALD VIRTUAL GLOBAL HEALTHCARE CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-30 08:25:00
| null |
SAN DIEGO, JULY 30, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, IS PROUD TO ANNOUNCE THE ADDITION OF MS. ANA HOOKER AS AN ADDITIONAL INDEPENDENT MEMBER TO ITS BOARD OF DIRECTORS, EFFECTIVE JULY 29, 2021.
|
EXAGEN APPOINTS ANA HOOKER TO BOARD OF DIRECTORS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-29 08:25:00
| null |
SAN DIEGO, JULY 29, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE CANACCORD GENUITY 41ST ANNUAL GROWTH CONFERENCE, WHICH TAKES PLACE AUGUST 10-12, 2021. RON ROCCA, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND KAMAL ADAWI, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT ON THURSDAY, AUGUST 12 AT 12:00 PM EST.
|
EXAGEN INC. TO PARTICIPATE IN THE CANACCORD GENUITY 41ST ANNUAL GROWTH CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-26 16:06:00
| null |
SAN DIEGO, JULY 26, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, WILL RELEASE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021 AFTER THE MARKET CLOSE ON MONDAY, AUGUST 9, 2021. RON ROCCA, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, KAMAL ADAWI, CHIEF FINANCIAL OFFICER, AND MARK HAZELTINE, CHIEF OPERATING OFFICER, WILL HOST A CONFERENCE CALL TO REVIEW THE COMPANY'S RESULTS AT 4:30 PM EASTERN TIME (1:30 PM PACIFIC TIME).
|
EXAGEN TO ANNOUNCE SECOND QUARTER 2021 FINANCIAL RESULTS ON AUGUST 9, 2021
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-13 16:05:00
| null |
SAN DIEGO, JULY 13, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, ANNOUNCED TODAY THE PUBLICATION OF THEIR LATEST CLINICAL UTILITY STUDY IN LUPUS & SCIENCE MEDICINE, FOUND HERE: HTTPS://LUPUS.BMJ.COM/CONTENT/8/1/E000528.FULL. THIS MULTI-CENTER STUDY DEMONSTRATED THAT THE AVISE LUPUS TEST HELPED INCREASE CONFIDENCE IN RULING-IN AND RULING-OUT SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN PATIENTS SUSPECTED OF THIS DISEASE AND INFORMED APPROPRIATE TREATMENT DECISIONS.
|
AVISE® LUPUS TEST DEMONSTRATES STATISTICALLY SIGNIFICANT CLINICAL UTILITY IN ACHIEVING A DEFINITIVE SLE DIAGNOSIS AND POSITIVELY IMPACTS TREATMENT DECISIONS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-18 08:29:00
| null |
SAN DIEGO, JUNE 18, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, IS PROUD TO ANNOUNCE THE COMPANY'S STOCKHOLDERS APPROVED THE ELECTION OF MR. FRANK STOKES AS AN ADDITIONAL INDEPENDENT MEMBER TO ITS BOARD OF DIRECTORS AT THE ANNUAL MEETING HELD ON JUNE 17, 2021. MR. STOKES WILL ALSO SERVE AS CHAIR OF THE AUDIT COMMITTEE.
|
EXAGEN ELECTS FRANK STOKES TO BOARD OF DIRECTORS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-24 16:05:00
| null |
SAN DIEGO, MAY 24, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED ITS PARTICIPATION IN THE WILLIAM BLAIR 41ST ANNUAL GROWTH STOCK CONFERENCE WHICH TAKES PLACE JUNE 1-3, 2021. RON ROCCA, EXAGEN'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND KAMAL ADAWI, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT ON WEDNESDAY, JUNE 2 AT 11:20 AM EDT.
|
EXAGEN INC. TO PARTICIPATE IN THE WILLIAM BLAIR 41ST ANNUAL GROWTH STOCK CONFERENCE
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-11 16:05:00
| null |
QUARTERLY RECORDS: AVISE® CTD VOLUMES, ORDERING HEALTHCARE PROVIDERS AND ADOPTERS
|
EXAGEN INC. REPORTS FIRST QUARTER 2021 RESULTS
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-29 08:25:00
| null |
SAN DIEGO, MARCH 29, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), AN ORGANIZATION DEDICATED TO TRANSFORMING THE CARE CONTINUUM FOR PATIENTS SUFFERING FROM AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT IT WILL COLLABORATE WITH EMORY UNIVERSITY ON A NEW STUDY ABOUT THE LONG-TERM EFFECTS OF COVID-19 INFECTION IN THE DEVELOPMENT OF AUTOIMMUNE DISEASES. EMORY IS WIDELY ACKNOWLEDGED AS A LEADING RESEARCH INSTITUTION IN THE STUDY OF VARIOUS AUTOIMMUNE DISEASES, INCLUDING LUPUS.
|
EXAGEN INC. ANNOUNCES STUDY ON THE LONG-TERM EFFECTS OF COVID-19 INFECTION IN THE DEVELOPMENT OF AUTOIMMUNE DISEASES
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-25 16:15:00
| null |
SAN DIEGO, MARCH 25, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED THAT IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 4,255,000 SHARES OF ITS COMMON STOCK, INCLUDING 555,000 SHARES SOLD PURSUANT TO THE UNDERWRITERS' FULL EXERCISE OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES, AT A PRICE TO THE PUBLIC OF $16.25 PER SHARE. THE GROSS PROCEEDS TO EXAGEN FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, WERE APPROXIMATELY $69.1 MILLION.
|
EXAGEN INC. ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK, INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-22 22:01:00
| null |
SAN DIEGO, MARCH 22, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3,700,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $16.25 PER SHARE. ALL OF THE SHARES TO BE SOLD IN THE OFFERING ARE TO BE SOLD BY EXAGEN. THE GROSS PROCEEDS TO EXAGEN FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, ARE EXPECTED TO BE $60.1 MILLION. IN ADDITION, EXAGEN HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 555,000 SHARES OF COMMON STOCK. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT MARCH 25, 2021, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.
|
EXAGEN INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-22 16:05:00
| null |
SAN DIEGO, MARCH 22, 2021 (GLOBE NEWSWIRE) -- EXAGEN INC. (NASDAQ: XGN), A LEADING PROVIDER OF AUTOIMMUNE TESTING SOLUTIONS, TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING. IN ADDITION, EXAGEN INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF COMMON STOCK OFFERED IN THE PUBLIC OFFERING. ALL OF THE SHARES TO BE SOLD IN THE OFFERING ARE TO BE SOLD BY EXAGEN. THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.
|
EXAGEN INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
|
XGN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.